Skip to main content

Month: March 2020

InsuraGuest Technologies Spotlighted in Broadcast on Crucial Need for Coverage of Vacation-Rental Insurance Gaps

NEW YORK, March 27, 2020 (GLOBE NEWSWIRE) — via NetworkNewsAudio – InsuraGuest Technologies Inc. (TSX.V: ISGI) announces the availability of a broadcast titled, “Growing Vacation Industry Fosters Demand for Integrated Support Services.”To hear the AudioPressRelease from NetworkNewsAudio, visit:  http://nnw.fm/J69Zn.To read the full editorial, visit: http://nnw.fm/Is8lC.In the United States alone, an estimated 4.5 million second homes are managed by rental companies. Every day, travelers turn to agents to help them with the administration of holiday and vacation travel. InsuraGuest Technologies Inc. (TSX.V: ISGI) was established to provide a vital part of that vacation ecosystem.Any player in the vacation industry faces the risk of liability in the event of guests injuring themselves. Additional features and facilities, which are...

Continue reading

Aravive Reports Fourth Quarter and Twelve Months Ended December 31, 2019 Financial Results and Provides Recent Corporate Updates

AVB-500 Phase 1b dose escalation ongoing at 20 mg/kg dose in platinum resistant ovarian cancer with potential for topline data in summer 2020Company announces clinical trial updates for clear cell renal cell carcinoma and IgA Nephropathy studiesCurrent cash runway expected to fund company into 2022HOUSTON, March 27, 2020 (GLOBE NEWSWIRE) — Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis, announced recent corporate updates and financial results for the fourth quarter and twelve months ended December 31, 2019.With the recent and rapidly evolving impact of COVID-19 on patient recruitment in clinical trials and considering patient safety and trial integrity, Aravive has decided to make certain changes...

Continue reading

Martela to withdraw its outlook for 2020 published on February 7, 2020

In its financial statements published on 7 February 2020, Martela Oyj estimated its turnover and operating result in 2020 to be slightly higher than in the previous year.The company now estimates that the ongoing coronavirus pandemic has significantly weakened the outlook in all market areas, and it is highly unlikely that the company’s earlier guidance will actualise.Martela will withdraw its 7 February 2020 outlook due to the estimated impact of the coronavirus pandemic. Due to the prevailing circumstances, it is not possible to make an accurate estimate of the company’s full-year turnover and operating result. Martela will publish a guidance for 2020 once a reliable estimate on the impacts can be made.These are exceptional times with the coronavirus spreading around the world. The health and wellbeing of our employees and...

Continue reading

Martela peruu 7.2.2020 antamansa tulosohjeistuksen vuodelle 2020

Martela Oyj arvioi 7.2.2020 julkaistussa tilinpäätöstiedotteessaan liikevaihdon ja liiketuloksen vuonna 2020 olevan edellisvuotista hieman korkeampi.Martela OyjMatti RantaniemiCEOLisätiedotMatti Rantaniemi, CEO, puh. +358 50 465 8194Kalle Lehtonen, Talousjohtaja +358 400 539 968JakeluNasdaq OMX HelsinkiKeskeiset tiedotusvälineetwww.martela.comMissiomme ”better working” ja visiomme ”people centric workplaces” määrittelevät strategisen suuntamme. Martela toimittaa käyttäjälähtöisiä työympäristöjä, joissa käyttäjät ja heidän hyvinvointi ovat keskiössä. Keskitymme Pohjoismaihin, sillä yhteisen avoimen työkulttuuritaustamme ja tarpeidemme myötä Pohjoismaat ovat hybridien työympäristöjen edelläkävijöitä.

Continue reading

Data Respons ASA: Annual Report 2019

The Board of Directors of Data Respons ASA approved the annual report for 2019 on 26 March 2020. There are no significant changes compared to the preliminary financial statements for 2019 published on 30 January 2020 at the Q4 2019 presentation. The Annual Report is subject to approval by the annual general meeting.A PDF-version of the annual report is attached and is also available on our webpage: www.datarespons.com/investors For further information: Kenneth Ragnvaldsen, CEO, Data Respons ASA, tel. +47 913 90 918.Rune Wahl, CFO, Data Respons ASA, tel. + 47 950 36 046

Continue reading

Passage Bio to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day

PHILADELPHIA, March 27, 2020 (GLOBE NEWSWIRE) — Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that management will participate in the virtual Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day on Friday, April 3, 2020.About Passage BioPassage Bio is a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company is based in Philadelphia, PA and has a research, collaboration and license agreement with the University of Pennsylvania (Penn) and its Gene Therapy Program (GTP). The GTP conducts IND-enabling preclinical work and Passage Bio conducts all clinical development,...

Continue reading

SmartCentres Receives TSX Approval to Proceed with Normal Course Issuer Bid

TORONTO, March 27, 2020 (GLOBE NEWSWIRE) — SmartCentres Real Estate Investment Trust (“SmartCentres” or the “Trust”) (TSX:SRU.UN) announced today that the Toronto Stock Exchange (the “TSX”) has accepted the notice filed by SmartCentres to establish a normal course issuer bid (“NCIB”) program. The NCIB program commences on March 31, 2020 and will terminate on March 30, 2021, or on such earlier date as SmartCentres may complete its purchases pursuant to a Notice of Intention filed with the TSX.  Under the NCIB program, SmartCentres is authorized to purchase up to 6,500,835 of its variable voting units (“Units”) (out of the 144,407,124 Units outstanding as at March 23, 2020) representing approximately 5% of the public float as at March 23, 2020, by way of normal course purchases effected through the facilities of the TSX and/or alternative...

Continue reading

SurveyMonkey Brings on Key Leadership in Marketing, Investor Relations, and Data & Analytics

SAN MATEO, Calif., March 27, 2020 (GLOBE NEWSWIRE) — SurveyMonkey (Nasdaq: SVMK) today announced new additions to its leadership team, including Karen Budell as vice president of brand marketing, Gary Fuges as vice president of investor relations, and Amit Sethi as vice president of data. The strategic hires will bring their wealth of knowledge and help accelerate SurveyMonkey’s disruption of both the customer experience (CX) and market research markets.“Karen, Gary and Amit are veterans in their respective fields and bring a track record of building successful teams throughout their careers,” said Zander Lurie, chief executive officer at SurveyMonkey. “Their roles are crucial as we expand our enterprise product suite to provide the best-in-class customer experience and market research solutions. We are transforming the CX industry,...

Continue reading

Allied Corp. Announces Appointment of Chief Financial Officer

KELOWNA, British Columbia, March 27, 2020 (GLOBE NEWSWIRE) — Allied Corp. (“Allied” or the “Company”) (OTCQB: ALID), an international medical cannabis company focused on creating and providing targeted cannabinoid health solutions to address today’s medical issues, today announced the appointment of Chief Financial Officer Mr. Ryan Maarschalk, Bsc, CPA. Mr. Maarschalk is a driven leader with multifaceted communication skills, and a proven track record of successfully working with senior leadership to achieve growth. Mr. Maarschalk uses his entrepreneurship experience to communicate financial information for real life decision making. Some of Mr. Maarschalk’s past experience includes merger and acquisition activities to successfully close the acquisition of IMPACT Radio Accessories to private equity for $23M,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.